No­var­tis takes an­oth­er stride to­ward Alex­ion's turf with PhI­II PNH win

Look­ing to break in­to a rare dis­ease field that As­traZeneca sub­sidiary Alex­ion has dom­i­nat­ed for years, No­var­tis says its oral drug best­ed an­ti-C5 ther­a­pies in a Phase III tri­al for parox­ys­mal noc­tur­nal he­mo­glo­bin­uria pa­tients.

The com­pa­ny didn’t break down the num­bers, stick­ing to the topline win on both co-pri­ma­ry end­points, mea­sur­ing the pro­por­tion of pa­tients record­ing two dif­fer­ent lev­els of he­mo­glo­bin in­creas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER